{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:06:43Z","timestamp":1791356803364,"version":"4.3.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The activating BRAF mutation V600E occurs in 8%\u201312% of metastatic colorectal cancers (mCRC) and is associated with peritoneal carcinomatosis (PC) and poor prognosis. Targeted inhibition with the oral BRAF inhibitor encorafenib, combined with intravenous cetuximab targeting epithelial growth factor receptor (EGFR) and standard chemotherapy FOLFOX, has improved outcomes and received FDA approval in 2025 based on results from the phase III BREAKWATER trial. We report a 26-year-old male with rapidly progressive, BRAF V600E-mutant, microsatellite-stable (MSS) rectal adenocarcinoma, liver metastases, and PC presenting with bowel obstruction and inability for oral intake. To enable targeted therapy, encorafenib was administered rectally and via nasogastric tube, together with intravenous cetuximab and FOLFOX (FOLFOX+EC). Most adverse events (AEs) were present before treatment and improved during FOLFOX+EC, indicating tumor association. Severe AEs included emesis, fatigue, pain, and elevated cholestatic liver enzymes. Treatment-related AEs were manageable with anaemia (\u00b03), neutropenia (\u00b04), and thrombocytopenia (\u00b01). No encorafenib-specific toxicities (rash, pyrexia, QTc prolongation, or ocular effects) were observed. Pharmacokinetic analysis showed trough plasma exposure comparable to oral dosing in patients without PC, and CT imaging at weeks 4 and 8 revealed early tumor shrinkage. This case demonstrates that rectal and nasogastric administration of encorafenib is feasible, achieves therapeutic plasma concentrations, and induces objective and clinical remission in the context of FOLFOX+EC. Short-term safety appeared manageable, though increased infection risk cannot be excluded.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag103","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:23:37Z","timestamp":1774869817000},"source":"Crossref","is-referenced-by-count":2,"title":["Gastric and rectal administration of encorafenib with targeted chemotherapy against BRAF V600E\u2013mutant rectal cancer with bowel obstruction"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9391-7773","authenticated-orcid":false,"given":"Maximilian Alexander","family":"Funk","sequence":"first","affiliation":[{"name":"Department of Medicine III, LMU University Hospital Munich , Munich, 81377,","place":["Germany"]},{"name":"Comprehensive Cancer Center Munich , Munich, 81377,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ) , Heidelberg, Munich, 80336,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF) , Munich, 81377,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1349-3321","authenticated-orcid":false,"given":"Volker","family":"Heinemann","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Munich , Munich, 81377,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7391-7280","authenticated-orcid":false,"given":"Veit","family":"B\u00fccklein","sequence":"additional","affiliation":[{"name":"Department of Medicine III, LMU University Hospital Munich , Munich, 81377,","place":["Germany"]},{"name":"Comprehensive Cancer Center Munich , Munich, 81377,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF) , Munich, 81377,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-702X","authenticated-orcid":false,"given":"Stefan Karl","family":"Alig","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen , Essen, 45147,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site Essen and German Cancer Research Centre (DKFZ) , Heidelberg, Essen, 45147,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3580-2313","authenticated-orcid":false,"given":"Kathrin","family":"Heinrich","sequence":"additional","affiliation":[{"name":"Department of Medicine III, LMU University Hospital Munich , Munich, 81377,","place":["Germany"]},{"name":"Comprehensive Cancer Center Munich , Munich, 81377,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ) , Heidelberg, Munich, 80336,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF) , Munich, 81377,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Medicine III, LMU University Hospital Munich , Munich, 81377,","place":["Germany"]},{"name":"Comprehensive Cancer Center Munich , Munich, 81377,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ) , Heidelberg, Munich, 80336,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF) , Munich, 81377,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Krenmayr","sequence":"additional","affiliation":[{"name":"Department of Medicine III, LMU University Hospital Munich , Munich, 81377,","place":["Germany"]},{"name":"Comprehensive Cancer Center Munich , Munich, 81377,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ) , Heidelberg, Munich, 80336,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF) , Munich, 81377,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3096-4305","authenticated-orcid":false,"given":"Benoit","family":"Blanchet","sequence":"additional","affiliation":[{"name":"Service de Biologie du M\u00e9dicament et Toxicologie, CARPEM, H\u00f4pital Cochin, AP-HP , Paris, Paris, 75014,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, CNRS, INSERM CiTCoM , Paris, 75006,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang Gerhard","family":"Kunz","sequence":"additional","affiliation":[{"name":"Department of Radiology, LMU University Hospital Munich , Munich, 81377,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5706-8258","authenticated-orcid":false,"given":"Sebastian","family":"Theurich","sequence":"additional","affiliation":[{"name":"Department of Medicine III, LMU University Hospital Munich , Munich, 81377,","place":["Germany"]},{"name":"Comprehensive Cancer Center Munich , Munich, 81377,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ) , Heidelberg, Munich, 80336,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF) , Munich, 81377,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[{"name":"Department of Medicine III, LMU University Hospital Munich , Munich, 81377,","place":["Germany"]},{"name":"Comprehensive Cancer Center Munich , Munich, 81377,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ) , Heidelberg, Munich, 80336,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF) , Munich, 81377,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4755-0179","authenticated-orcid":false,"given":"Julian Walter","family":"Holch","sequence":"additional","affiliation":[{"name":"Department of Medicine III, LMU University Hospital Munich , Munich, 81377,","place":["Germany"]},{"name":"Comprehensive Cancer Center Munich , Munich, 81377,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ) , Heidelberg, Munich, 80336,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF) , Munich, 81377,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"2026042618470463500_oyag103-B1","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature."},{"key":"2026042618470463500_oyag103-B2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol."},{"key":"2026042618470463500_oyag103-B3","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.annonc.2021.03.206","article-title":"Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines","volume":"32","author":"Grothey","year":"2021","journal-title":"Ann Oncol."},{"key":"2026042618470463500_oyag103-B4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/1078-0432.CCR-16-0140","article-title":"BRAF V600E mutant colorectal cancer subtypes based on gene expression","volume":"23","author":"Barras","year":"2017","journal-title":"Clin Cancer Res."},{"key":"2026042618470463500_oyag103-B5","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"key":"2026042618470463500_oyag103-B6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of Colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature."},{"key":"2026042618470463500_oyag103-B7","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","article-title":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer\u202f: a randomized phase 3 trial","volume":"31","author":"Kopetz","year":"2025","journal-title":"Nat. Med"},{"key":"2026042618470463500_oyag103-B8","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","article-title":"Encorafenib, cetuximab, and mFOLFOX6 in BRAF-Mutated colorectal cancer","volume":"392","author":"Elez","year":"2025","journal-title":"N Engl J Med."},{"key":"2026042618470463500_oyag103-B9","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.3390\/cancers15235641","article-title":"Peritoneal metastasis: A dilemma and challenge in the treatment of metastatic colorectal cancer","volume":"15","author":"Xia","year":"2023","journal-title":"Cancers"},{"key":"2026042618470463500_oyag103-B10","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1002\/cncr.26086","article-title":"Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer","volume":"117","author":"Tran","year":"2011","journal-title":"Cancer."},{"key":"2026042618470463500_oyag103-B11","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026042618470463500_oyag103-B12","author":"Food and Drug Administration","year":"2018"},{"key":"2026042618470463500_oyag103-B13","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1158\/0008-5472.CAN-05-0404","article-title":"Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers","volume":"65","author":"Samowitz","year":"2005","journal-title":"Cancer Res"},{"key":"2026042618470463500_oyag103-B14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41586-024-07769-3","article-title":"Prognostic genome and transcriptome signatures in colorectal cancers","volume":"633","author":"Nunes","year":"2024","journal-title":"Nature."},{"key":"2026042618470463500_oyag103-B15","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/jnci\/djab042","article-title":"BRAF V600EMutation in First-Line metastatic colorectal cancer: an analysis of individual patient data from the ARCAD database","volume":"113","author":"Cohen","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2026042618470463500_oyag103-B16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.clcc.2024.05.007","article-title":"Peritoneal carcinomatosis in colorectal cancer: review and update of current clinical data","volume":"23","author":"Blaj","year":"2024","journal-title":"Clin Colorectal Cancer."},{"key":"2026042618470463500_oyag103-B17","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1111\/codi.15003","article-title":"Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis","volume":"22","author":"Narasimhan","year":"2020","journal-title":"Colorectal Dis."},{"key":"2026042618470463500_oyag103-B18","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1186\/s12967-024-05467-2","article-title":"Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer","volume":"22","author":"Lund-Andersen","year":"2024","journal-title":"J Transl Med"},{"key":"2026042618470463500_oyag103-B19","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1200\/JCO.2024.42.16_suppl.3531","article-title":"Patients with early-onset metastatic colorectal cancer as an emerging distinctive clinical and molecular phenomenon","volume":"42","author":"Pretta","year":"2024","journal-title":"JCO."},{"key":"2026042618470463500_oyag103-B20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1200\/JCO.2024.42.3_suppl.195","article-title":"Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular profile","volume":"42","author":"Pretta","year":"2024","journal-title":"JCO."},{"key":"2026042618470463500_oyag103-B21","author":"European Medicines Agency","year":"2018"},{"key":"2026042618470463500_oyag103-B22","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.3389\/fphar.2019.01196","article-title":"Physiological and pharmaceutical considerations for rectal drug formulations","volume":"10","author":"Hua","year":"2019","journal-title":"Front Pharmacol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag103\/67714567\/oyag103.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag103\/67714567\/oyag103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag103\/67714567\/oyag103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T22:47:08Z","timestamp":1777243628000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag103\/8571366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag103","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,3,31]]},"article-number":"oyag103"}}